Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospitalopen accessAssessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital
- Other Titles
- Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital
- 박미선; 양영모; 박기현; 윤현옥; 김주신; 최은주
- Issue Date
- Direct-acting antiviral treatment; effectiveness; hepatitis C virus; safety; sustained virological response (SVR)
- 한국임상약학회지, v.32, no.3, pp.191 - 203
- Journal Title
- Start Page
- End Page
- Background: Direct-acting antivirals are recommended for the treatment of chronic hepatitis C virus in Korea. However, evaluationof direct-acting antiviral regimens in a real-world setting is limited. The aims of this study were to investigate the effectiveness andsafety of direct-acting antiviral treatment in Korean patients infected with chronic hepatitis C virus genotype 1b or 2 at a tertiary carehospital. Methods: This was a retrospective study conducted with patient data obtained between August 2015 and August 2019 atJeonbuk National University Hospital. The primary effectiveness endpoint was sustained virological response 12 weeks posttreatment(SVR12) via intention-to-treat (ITT) and modified intention-to-treat (mITT) analyses. Results: Of the 270 patients, 47.0%were infected with genotype 1b and 53.0% with genotype 2. ITT analysis revealed that SVR12 was achieved in 78.9% of all patients,77.2% in genotype 1b patients, and 80.4% in genotype 2 patients. Of the 21.1% of all patients who did not achieve SVR12, themajority of treatment failures were non-virologic failures (19.7%). mITT analysis revealed that SVR12 was achieved in 98.2% of allpatients, 98.0% in genotype 1b patients, and 98.3% in genotype 2 patients. Almost half of all patients experienced one or moreadverse events (43.3%), leading to 2.6% discontinuing scheduled treatment. The most common adverse event was anemia.
Conclusions: Direct-acting antiviral-based treatment regimens showed high effectiveness and safety. Non-virological factors, suchas premature treatment discontinuation due to adverse events or loss of follow-up, were the major disruptors in achieving SVR12.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 약학대학 > 약학과 > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.